Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma

Yoshihiko Tasaki, Shuzo Hamamoto, Yoko Furukawa-Hibi, Takahiro Yasui